Chromocell Therapeutics Corporation (CHRO)
USD 1.32
(0.76%)
USD 1.32
(0.76%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -6.86 Million USD | -196.02% |
| 2022 | -2.31 Million USD | -176.3% |
| 2021 | -839 Thousand USD | 38.03% |
| 2020 | -1.35 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -1.76 Million USD | 8.78% |
| 2024 Q1 | -1.93 Million USD | 50.14% |
| 2023 Q3 | -1.29 Million USD | -66.21% |
| 2023 Q1 | -914.58 Thousand USD | -31.22% |
| 2023 FY | -6.86 Million USD | -196.02% |
| 2023 Q2 | -777.16 Thousand USD | 15.03% |
| 2023 Q4 | -3.87 Million USD | -200.28% |
| 2022 Q4 | -696.98 Thousand USD | -34.33% |
| 2022 FY | -2.31 Million USD | -176.3% |
| 2022 Q3 | -518.83 Thousand USD | -74.89% |
| 2022 Q2 | -296.66 Thousand USD | -3.06% |
| 2022 Q1 | -287.84 Thousand USD | 0.0% |
| 2021 FY | -839 Thousand USD | 38.03% |
| 2020 FY | -1.35 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -31.91 Million USD | 78.499% |
| Ampio Pharmaceuticals, Inc. | -9.51 Million USD | 27.902% |
| Armata Pharmaceuticals, Inc. | -40.89 Million USD | 83.218% |
| Actinium Pharmaceuticals, Inc. | -51.92 Million USD | 86.783% |
| Azitra, Inc. | -7.61 Million USD | 9.901% |
| Can-Fite BioPharma Ltd. | -8.19 Million USD | 16.263% |
| Calidi Biotherapeutics, Inc. | -28.99 Million USD | 76.33% |
| CEL-SCI Corporation | -31.47 Million USD | 78.198% |
| iBio, Inc. | -16.63 Million USD | 58.745% |
| Lineage Cell Therapeutics, Inc. | -24.73 Million USD | 72.255% |
| MAIA Biotechnology, Inc. | -20.18 Million USD | 65.999% |
| Matinas BioPharma Holdings, Inc. | -23.76 Million USD | 71.126% |
| Navidea Biopharmaceuticals, Inc. | -14.05 Million USD | 51.161% |
| NovaBay Pharmaceuticals, Inc. | -5 Million USD | -37.163% |
| NanoViricides, Inc. | -8.51 Million USD | 19.42% |
| Oragenics, Inc. | -20.9 Million USD | 67.174% |
| BiomX Inc. | -27.68 Million USD | 75.213% |
| BiomX Inc. | -27.68 Million USD | 75.213% |
| Protalix BioTherapeutics, Inc. | 10.46 Million USD | 165.605% |
| Palatin Technologies, Inc. | -22.49 Million USD | 69.496% |
| Scorpius Holdings, Inc. | -42.03 Million USD | 83.674% |
| Theriva Biologics, Inc. | -21.43 Million USD | 67.98% |